Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.

Christoph WannerSilvio E InzucchiBernard ZinmanAudrey Koitka-WeberMichaela MattheusJyothis T GeorgeMaximilian von EynattenSibylle J Hauskenull null

Published in: Diabetes, obesity & metabolism (2020)

Empagliflozin may improve CV and kidney outcomes and slow the progression of kidney disease in type 2 diabetes patients with DKD, irrespective of its clinical form, both with or without the presence of overt albuminuria.

Keyphrases

type diabetes
glycemic control
clinical trial
cardiovascular disease
insulin resistance
metabolic syndrome
phase ii
skeletal muscle
open label